Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B
Virus Infection
Table 1
Baseline clinical characteristics of 144 patients received nucleos(t)de analogues with chronic HBV-infected liver disease at the time of enrollment.
Median (range)
value
ADV group ()
Non-ADV group ()
At the time of enrollment
Age (yr)
52 (29–78)
55 (28–83)
0.8368
Sex (male/female)
15/5
82/42
0.5974
HBV genotype (A/B/C/F/n.d)
2/2/12/1/3
3/26/65/0/30
0.8671
HBV DNA (log10 copies/mL)
2.1 > (negative–3.0)
2.1 > (negative–6.2)
0.1896
Platelet count (×103/m3)
16.5 (10.2–31.0)
16.8 (3.4–31.5)
0.1987
ALT (IU/L)
26 (10–60)
20 (8–124)
0.1117
Alb (g/dL)
4.4 (4–5.3)
4.4 (1.8–5.2)
0.9154
Cirrhosis (presence/absence)
5/15
30/94
0.8392
At the time of starting ADV or ETV
Serum creatinine (mg/dL)
0.8 (0.6–1.2)
0.76 (0.52–1.30)
0.3853
Follow-up duration (month)
103 (37–141)
40 (12–152)
Duration of nucleos(t)ide analogue therapy (month)
103 (37–141)
34 (12–117)
Duration of adefovir administration (month)
73 (12–107)
Propensity score
0.197 (0.068–0.553)
0.108 (–0.514)
0.0018
ADV: adefovir dipivoxil; non-ADV: lamivudine or entecavir.